THE STATE OF THE LIFE SCIENCES
The Life Sciences sector has continued to change rapidly as the world connects companies and technologies like never before. Throughout this change, the sector has been under many different pressures including economic forces, government regulations, and operational barriers.
Regardless of the pressures, the life science field has fielded a number of changes in recent years. Whether it's the mega-mergers evident in the pharmaceutical sector, the increasing debate over payment policies of emerging treatments, or the evolving relationship between the public and private health sectors, successful companies must have a robust capacity to adapt to scientific, commercial, and operational changes.
Moreover, with the inevitable digital revolution in life sciences, to continue to generate value, biopharma, healthcare IT, and medtech companies have been looking at implementing newer approaches such as data-driven technologies, automation, AI/ML and more to reduce drug development timelines, facilitate personalized treatment modalities, and create an improved patient experience.
CBE has worked with industry leaders such as Pfizer, Roche, and more to conduct research and provide strategy insights on pipeline analysis, data-based diagnostics, digital healthcare, direct-to-consumer healthcare, and more.